Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease

Cohort study (n=14,792) found lowering serum urate level to <6 mg/dL using urate-lowering therapy (ULT- mainly allopurinol & febuxostat) was not associated with a higher risk of severe or end-stage kidney disease progression vs those who did not achieve this level with ULT

SPS commentary:

The 5-year risk of severe or end-stage kidney disease was 10.32% for those who achieved the target serum urate level and 12.73% for those who did not. Compared with those not achieving the target level, the adjusted 5-year risk difference and HR of severe or end-stage kidney disease for patients achieving the target serum urate level was −2.41% (95% CI, −4.61% to −0.21%) and 0.89 (95% CI, 0.80 to 0.98), respectively.

JAMA Internal Medicine